Another Masterstroke From Merck & Co., Inc. (MRK), OPKO Health, Inc. (OPK) – The RNS Daily

This post was originally published on this site

A look at MRK technical analysis shows that its 14-day Relative Strength Index (RSI) is in a oversold zone after reaching 29.88 point. Its trading volume has added 2298362 shares compared to readings over the past three months as it recently exchanged 12818362 shares. This means there is improved activity from short-term traders as per session, its average trading volume is 10520000 shares, and this is 1.22 times the normal volume.

Merck & Co., Inc. (NYSE:MRK) climbed by 7.03% over the past three months which led to its overall six-month increase to stand at 14.86%. The equity price sank -2.99% this week, a trend that has led to both investors and traders taking note of the stock. A look at its monthly performance shows that its shares have recorded a -3.73% fall over the past 30 days. Over the past 12 months the stock has embarked on a rally that has seen it rise 37.36% and is now up by 2.77% since start of this year.

The shares of Merck & Co., Inc. dropped by -6.34% or -$5.32 from its last recorded high of $83.85 which it attained on January 04 to close at $78.53 per share. Over the past 52 weeks, the shares of Merck & Co., Inc. has been trading as low as $56.26 before witnessing a massive surge by 39.58% or $22.27. This price movement has led to the MRK stock receiving more attention and has become one to watch out for. It dipped by -1.13% on Monday and this got the market worried. The stock’s beta now stands at 0.65 and when compared to its 200-day moving average and its 50-day moving average, MRK price stands 7.25% above and -2.53% below respectively. Its average daily volatility for this week is 1.28% which is less than the 1.29% recorded over the past month.

Experts from research firms are bullish about the near-term performance of Merck & Co., Inc. (MRK) with most of them predicting a $86.64 price target on a short-term (12 months) basis. The average price target by the analysts will see a 10.33% rise in the stock and would lead to MRK’s market cap to surge to $225.26B. The stock has been rated an average 1.8, which roughly stands towards the bullish end of the spectrum. Reuters looked into the 17 analysts that track Merck & Co., Inc. (NYSE:MRK) and find out that 3 of them rated it as a Hold. 14 of the 14 analysts rated it as a Buy or a Strong Buy while 0 advised investors to desist from buying the stock or sell it if they already possess it.

The price of OPKO Health, Inc. (NASDAQ:OPK) currently stands at $2.46 after it went down by $-0.02 or -0.81% and has found a strong support at $2.44 a share. If the OPK price drops below that critical support, then it would lead to a bearish trend. In the short-term, a dip below the $2.42 mark would also be bad for the stock as it means that the stock would plunge by 1.63% from its current position. However, if the stock price is able to trade above the resistance point around $2.5, then it could likely surge higher to try and break the upward resistance which stands at $2.54 a share. Its average daily volatility over the past one month stands at 3.87%. The stock has plunged by 0% from its 52-weeks high of $2.46 which it reached on Jul. 17, 2018. In general, it is 4.88% above its 52-weeks lowest point which stands at $2.34 and this setback was observed on Dec. 27, 2018.

Analysts have predicted a price target for OPKO Health, Inc. (OPK) for 1 year and it stands at an average $5.33/share. This means that it would likely increase by 116.67% from its current position. The current price of the stock has been moving between $2.46 and $2.52. Some brokerage firms have a lower target for the stock than the average, with one of them setting a price target as low as $5. On the other hand, one analyst is super bullish about the price, setting a target as high as $6.

The OPK stock Stochastic Oscillator (%D) is at 29.51%, which means that it is currently oversold and its prices could jump very soon. The shares P/S ratio stands at 1.49 which compares to the 6.59 recorded by the industry or the 8.39 by the wider sector. The stock currently has an estimated price-earnings (P/E) multiple of 0, which is lower than the 0 multiple of 12-month price-earnings (P/E). The company’s earnings have gone up, with a quarterly increase rate of 3.4% over the past five years.

Analysts view OPKO Health, Inc. (NASDAQ:OPK) as a Buy, with 1.3 consensus rating. Reuters surveyed 3 analysts that follow OPK and found that 0 of those analysts rated the stock as a Hold. The remaining 3 were divided, with 3 analyst rating it as a Buy or a Strong Buy while 0 analysts advised investors to desist from buying OPKO Health, Inc. (OPK) shares or sell it if they already own it.

This post was originally published on *this site*